JP2024527288A5 - - Google Patents
Info
- Publication number
- JP2024527288A5 JP2024527288A5 JP2023579158A JP2023579158A JP2024527288A5 JP 2024527288 A5 JP2024527288 A5 JP 2024527288A5 JP 2023579158 A JP2023579158 A JP 2023579158A JP 2023579158 A JP2023579158 A JP 2023579158A JP 2024527288 A5 JP2024527288 A5 JP 2024527288A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- chain variable
- ccr8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/102324 | 2021-06-25 | ||
| CNPCT/CN2021/102324 | 2021-06-25 | ||
| CNPCT/CN2022/092803 | 2022-05-13 | ||
| CNPCT/CN2022/092803 | 2022-05-13 | ||
| PCT/CN2022/101000 WO2022268192A1 (en) | 2021-06-25 | 2022-06-24 | Anti-ccr8 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527288A JP2024527288A (ja) | 2024-07-24 |
| JP2024527288A5 true JP2024527288A5 (enExample) | 2025-07-02 |
Family
ID=84544143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579158A Pending JP2024527288A (ja) | 2021-06-25 | 2022-06-24 | 抗ｃｃｒ８抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240352134A1 (enExample) |
| EP (1) | EP4359442A4 (enExample) |
| JP (1) | JP2024527288A (enExample) |
| KR (1) | KR20240025013A (enExample) |
| CN (1) | CN117616046A (enExample) |
| TW (1) | TW202325732A (enExample) |
| WO (1) | WO2022268192A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| JPWO2024248037A1 (enExample) | 2023-05-30 | 2024-12-05 | ||
| CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| CN119080936B (zh) * | 2024-10-24 | 2025-05-23 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| AU2021244200A1 (en) * | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
-
2022
- 2022-06-24 KR KR1020247003056A patent/KR20240025013A/ko active Pending
- 2022-06-24 JP JP2023579158A patent/JP2024527288A/ja active Pending
- 2022-06-24 US US18/573,978 patent/US20240352134A1/en active Pending
- 2022-06-24 CN CN202280044035.8A patent/CN117616046A/zh active Pending
- 2022-06-24 WO PCT/CN2022/101000 patent/WO2022268192A1/en not_active Ceased
- 2022-06-24 TW TW111123764A patent/TW202325732A/zh unknown
- 2022-06-24 EP EP22827684.6A patent/EP4359442A4/en active Pending